GOAL OPTIMIZING WORKFLOW TO IMPROVE CARE

CHALLENGE

Patient wait time is a source of concern. Manual methods plus multiple instruments mean a longer time for results. These delays can lead to a decrease in available beds.

"[The BD MAX™ System]
makes a big difference ...
in how we manage our
patients and beds within
the hospital."

Consultant Microbiologist and Clinical Director for Pathology Hampshire Hospitals



HOW CAN YOU ACHIEVE MAX EFFICIENCY?

GET ANSWERS FOR MORE PATIENTS, FASTER.
THE BD MAX SYSTEM CAN HELP.



- LESS THAN
 1 1 MINUTE*
 HANDS-ON TIME
 PER SPECIMEN^{2,6}
- 15 MINUTES*

 HANDS-ON TIME
 PER RUN^{2,6}
 - OVER
 2 HOURS*
 WALK-AWAY TIME
 PER RUN⁶

TESTING FLEXIBILITY

- Run 1–24 samples and different assays at the same time^{2,5}
- Test a wide range of sample types⁶

STAFF PRODUCTIVITY THROUGH AUTOMATION

Offers simple implementation and standardized workflow⁶

OPPORTUNITY TO REDUCE TOTAL COST

• By enabling increased testing volume through streamlined workflow^{2,5,7}

^{*}Based on processing 24 samples.



REFERENCES:

- 1. Centers for Disease Control and Prevention. Recommendations for the laboratorybased detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*—2014. *MMWR Recomm Rep.* 2014;63(RR-02):1-19.
- Hirvonen JJ et al. Comparison of BD Max Cdiff and GenomEra C. difficile molecular assays for detection of toxigenic Clostridium difficile from stools in conventional sample containers and in FecalSwabs. EJCMID. 2015;34(5):1005-1009.
- 3. Mortensen JE et al. Comparison of time-motion analysis of conventional stool culture and the BD MAX Enteric Bacterial Panel (EBP). *BMC Clin Pathol*. 2015;15:9.
- **4.** Le Guern R et al. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic *Clostridium difficile* in fecal samples. *J Clin Microbiol.* 2012;50(9):3089-3090.
- 5. Bauman M. Transitioning from culture to molecular: implementation and integration of BD Max Enteric Bacterial Panel at Cincinnati Children's Hospital. ADVANCE Healthcare website. http://laboratory-manager.advanceweb.com/SharedResources/Downloads/2015/051815/bd_advertorial.pdf. Updated June 2015. Accessed June 1, 2016.
- **6.** Felder RA et al. Process evaluation of an open architecture real-time molecular laboratory platform. *J Lab Autom.* 2014;19(5):468-473.
- LeBlanc L et al. Cost-effectiveness and laboratory workload efficiency of 8 C difficile
 testing algorithms. Poster presented at: American Society for Microbiology; May
 30-June 2, 2015; New Orleans, LA.
- 8. Knabl L et al. Comparison of the BD MAX Enteric Bacterial Panel assay with conventional diagnostic procedures in diarrheal stool samples. *EJCMID*. 2016;35(1):131-136.

THE BD MAX SYSTEM CAN HELP WITH:

- Workflow efficiency for timely patient management¹⁻³
- Diagnostic **speed and accuracy** to aid in fast, appropriate treatment 1,2,4,5
- Testing **versatility** for a wide range of patients⁶

ASK YOUR BD REPRESENTATIVE HOW THE BD MAX SYSTEM CAN HELP YOU ACHIEVE MAXIMUM IMPACT.



BD Life Sciences Business Park Terre-Bonne Bâtiment A4, Route de Crassier 17 1262 Eysins, Switzerland bd.com/ds





HOW CAN YOU ACHIEVE



"Tests that take hours as opposed to days ... will have a positive patient impact."

Scientific Director of the Esoteric Testing/R&D Department Tampa General Hospital

IMPACT?





GOAL **IMPROVING PATIENT CARE WITH SPEED AND ACCURACY**


CHALLENGE

Traditional methods are slower, which can contribute to:

- Inappropriate or ineffective treatment
- Extended hospital stays for patients

"The advantages of the BD MAX™ System are that we are able to get results very quickly and correctly. Above all, it is very fast and gives us accurate results."

Clinical Microbiologist Akdeniz University Hospital



HOW CAN YOU ACHIEVE MAX PERFORMANCE?

MOLECULAR TESTING REDUCES TIME TO RESULT

FOR FAST,

LEADING TO TIMELY PATIENT MANAGEMENT'



- **HIGHER SENSITIVITY8**
- **FASTER TIME TO RESULT^{2,3}**

GOAL

REACHING MORE PATIENTS WITH THE RIGHT TEST AT THE RIGHT TIME

CHALLENGE

The lab needs one system with the ability to provide:

- A variety of syndromic testing options
- An expanding offering to keep up with emerging diagnostic requirements
- Tailored options based on specific patient needs

"One of the attractions of the BD MAX System was ... tests that are available, and future tests that could be put onto it."

Microbiology Manager Hampshire Hospital's NHS Foundation Trust



HOW CAN YOU ACHIEVE MAX VERSATILITY?

LEVERAGE CLINICALLY RELEVANT ASSAYS FOR A WIDE RANGE OF PATIENTS



THE BD MAX SYSTEM FEATURES

- A broad and flexible syndromic test selection
- An innovative assay pipeline, with continued investment in development of clinically relevant assays.
- A suite of Open System Reagents for User-Defined Protocols

A BROAD SUITE OF MOLECULAR SOLUTIONS

GASTROINTESTINAL

Focused Panels for Targeted Solutions

Enteric Bacterial Panel Enteric Parasite Panel Extended Enteric Bacterial Panel Enteric Viral Panels*

WOMEN'S HEALTH AND STI

Innovative Design for Clinical Impact

GBS

CT/GC/TV

Vaginal Panel (Bacterial Vaginosis, Candida, Trichomonas vaginalis)

HEALTHCARE-ASSOCIATED INFECTIONS

Test the Right Targets to Reduce Transmission

Cdiff

MRSA XT (with mecA/mecC resistance). StaphSR (with mecA/mecC resistance). Check-Points CPO*

OPEN SYSTEM REAGENTS

Open to Possibilities

Kits for the extraction of DNA & TNA allow for full automation of 'in-house' or other PCR assays including those available through BD Partner collaborations.

*Products under development, not available for sale or use. All products are CE marked in compliance with the European Directive for In Vitro Diagnostic Medical Devices (98/79/EC) unless otherwise noted.

IVD assays, research use only (RUO) assays and user-defined protocols (UDP) cannot be combined in the same rack.